FDA calendar · September 2020 · built from SEC filings

PDUFA dates September 2020: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in September 2020. The FDA calendar also recorded 12 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in September 2020

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

September 2020: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
September 1, 2020ONUREG (azacitidine)BMYFDA approval—ApprovedopenFDA Drugs@FDA
September 3, 2020Trulicity (dulaglutide)LLYLabel expansion—ApprovedopenFDA Drugs@FDA
September 9, 2020Trelegy Ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
September 18, 2020Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
September 18, 2020Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
September 22, 2020LINZESS® (linaclotide)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
September 24, 2020Kalydeco (ivacaftor)VRTXLabel expansion—ApprovedopenFDA Drugs@FDA
September 25, 2020Nucala (mepolizumab)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
September 25, 2020Xeljanz (tofacitinib citrate)PFEFDA approval—ApprovedopenFDA Drugs@FDA
September 25, 2020Xeljanz (tofacitinib citrate)PFELabel expansion—ApprovedopenFDA Drugs@FDA
September 29, 2020KHINDIVI® (hydrocortisone)ETONFDA approval—ApprovedopenFDA Drugs@FDA
September 29, 2020Aria® (golimumab)JNJLabel expansion—ApprovedopenFDA Drugs@FDA

September 2020: dated readouts

No events in this view.

Questions

What PDUFA dates are in September 2020?

0 PDUFA dates fell in September 2020. The FDA calendar also recorded 12 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.